BDBM665097 US20240116892, Compound I-61-a::US20240116892, Compound I-61-b

SMILES CN([C@@H]1CCN(C[C@H]1F)c1cnc2[nH]ncc2c1)C(=O)Nc1cc(cn(C)c1=O)C(F)(F)F

InChI Key InChIKey=JZXODPWAUKMMJZ-UHFFFAOYSA-N

Data  2 Kd

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 665097   

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665097(US20240116892, Compound I-61-b | US20240116892, Co...)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665097(US20240116892, Compound I-61-b | US20240116892, Co...)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent